CytomX Therapeutics. has been granted a patent for polypeptides featuring tandem substrates that include cleavable moieties for matrix metalloproteases and serine or cysteine proteases. The invention encompasses methods for creating and utilizing these polypeptides in various therapeutic, diagnostic, and prophylactic applications. GlobalData’s report on CytomX Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on CytomX Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. CytomX Therapeutics's grant share as of July 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Polypeptides with cleavable moieties for therapeutic applications
The granted patent US12049505B2 describes an isolated polypeptide that features a tandem substrate composed of two distinct cleavable moieties: a first cleavable moiety (CM1) that serves as a substrate for matrix metalloproteases (MMPs) and a second cleavable moiety (CM2) that acts as a substrate for either serine proteases (SPs) or cysteine proteases (CPs). The patent specifies that CM1 can include amino acid sequences such as AHGL or PRQV, while CM2 encompasses a variety of sequences, including SGR, LSGR, ARG, and others. The arrangement of these moieties can be either CM1-CM2 or CM2-CM1, allowing for flexibility in the polypeptide's structure.
Further claims within the patent detail additional specific sequences for CM2, including various combinations and lengths of amino acid sequences. The patent also outlines potential applications of the isolated polypeptide, including its conjugation to other agents. Notably, the patent identifies specific MMPs, such as MMP2, MMP9, and MMP14, as well as various SPs and CPs, including legumain, that can interact with the polypeptide. The comprehensive nature of the claims suggests a focus on the polypeptide's utility in therapeutic and diagnostic applications, leveraging its unique structural features and substrate specificity.
To know more about GlobalData’s detailed insights on CytomX Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
